TheraRadar

Competitive Density Analysis

Trial activity, Phase 3 concentration, and competitive dynamics by indication

Current Metrics: Based on ClinicalTrials.gov data (active trials, phases, sponsors).

Future Enhancement: True "white space" analysis (trials vs approved drugs) requires mapping FDA-approved drugs to our indication taxonomy. FDA labels use specific terms like "HER2+ metastatic breast carcinoma" while our taxonomy uses broader categories like "Breast Cancer". This mapping is in progress.

Highest Trial Activity

Most active indications by total trial count

Indication TA Active Trials Phase 3 Phase 2 Sponsors
Rheumatoid Arthritis Immunology 3942 884 2013 15
Ankylosing Spondylitis Immunology 3547 810 1822 15
Solid Tumor (Advanced) Oncology 3347 330 1748 15
Myocardial Infarction Cardiovascular 1653 389 754 15
Non-Hodgkin Lymphoma Oncology 1465 163 944 15
Breast Cancer Oncology 1434 296 858 15
NSCLC Oncology 1404 268 875 15
Colorectal Cancer Oncology 1095 177 714 15
ALL Oncology 1031 152 620 15
Erectile Dysfunction Urology 869 205 385 15
Prostate Cancer Oncology 863 152 538 15
Multiple Myeloma Oncology 662 104 397 15
AML Oncology 655 75 352 15
Pancreatic Cancer Oncology 643 71 413 15
Hepatocellular Carcinoma Oncology 608 92 379 15

Late-Stage Concentration

Highest Phase 3 activity (near-term competitive pressure)

Indication TA Phase 3 % of Trials Active Sponsors
Rheumatoid Arthritis Immunology 884 22% 3942 15
Ankylosing Spondylitis Immunology 810 23% 3547 15
Myocardial Infarction Cardiovascular 389 24% 1653 15
Solid Tumor (Advanced) Oncology 330 10% 3347 15
Breast Cancer Oncology 296 21% 1434 15
NSCLC Oncology 268 19% 1404 15
Erectile Dysfunction Urology 205 24% 869 15
Colorectal Cancer Oncology 177 16% 1095 15
Non-Hodgkin Lymphoma Oncology 163 11% 1465 15
ALL Oncology 152 15% 1031 15
Prostate Cancer Oncology 152 18% 863 15
Stroke Cardiovascular 152 42% 361 15

Concentrated Markets

Few sponsors running many trials (potential dominance or acquisition targets)

Indication TA Trials/Sponsor Active Sponsors
Rheumatoid Arthritis Immunology 262.8 3942 15
Ankylosing Spondylitis Immunology 236.5 3547 15
Solid Tumor (Advanced) Oncology 223.1 3347 15
Myocardial Infarction Cardiovascular 110.2 1653 15
Non-Hodgkin Lymphoma Oncology 97.7 1465 15
Breast Cancer Oncology 95.6 1434 15
NSCLC Oncology 93.6 1404 15
Colorectal Cancer Oncology 73 1095 15
ALL Oncology 68.7 1031 15
Erectile Dysfunction Urology 57.9 869 15

Fragmented Markets

Many sponsors competing (crowded, potentially commoditized)

Indication TA Sponsors Active Phase 3
Rheumatoid Arthritis Immunology 15 3942 884
Ankylosing Spondylitis Immunology 15 3547 810
Solid Tumor (Advanced) Oncology 15 3347 330
Myocardial Infarction Cardiovascular 15 1653 389
Breast Cancer Oncology 15 1434 296
Non-Hodgkin Lymphoma Oncology 15 1465 163
NSCLC Oncology 15 1404 268
COVID-19 Infectious Disease 15 185 59
Erectile Dysfunction Urology 15 869 205
ALL Oncology 15 1031 152

Showing top indications in each category

Upgrade to Pro for full competitive density analysis across 142 indications

See Pro Features

Methodology

Data Source: ClinicalTrials.gov (Phase 2-4 interventional drug trials, 2015+)

Active Trials: Status = Recruiting, Active, or Enrolling by Invitation

Trials/Sponsor: Average trials per company in that indication. Higher = concentrated market.

Phase 3 %: Proportion of active trials in Phase 3. Higher = more near-term competitive pressure.